Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

12/31/23 2:10:00 PM ET

$LAB

$SLGC

Biotechnology: Laboratory Analytical Instruments

Industrials

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $LAB alert in real time by email

Boston Millennia Partners ("Boston Millennia"), a significant shareholder of SomaLogic (the "Company") (NASDAQ:SLGC) today announced that it intends to vote against the Company's planned merger (the "Merger") with Standard BioTools Inc. (NASDAQ:LAB).

View source version on businesswire.com: https://www.businesswire.com/news/home/20231231077712/en/

Get the next $LAB alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$LAB
$SLGC

Company	Date	Price Target	Rating	Analyst
Standard BioTools Inc. $LAB	8/13/2025	$1.55	Buy → Hold	TD Cowen
Standard BioTools Inc. $LAB	2/27/2025		Overweight → Sector Weight	KeyBanc Capital Markets
Standard BioTools Inc. $LAB	4/16/2024	$3.50	Buy	TD Cowen
Standard BioTools Inc. $LAB	4/4/2024	$3.25	Buy	Jefferies
SomaLogic Inc. $SLGC	10/5/2023	$3.50 → $2.29	Buy → Hold	Jefferies
SomaLogic Inc. $SLGC	9/25/2023	$5.00 → $2.50	Buy → Hold	Canaccord Genuity
Standard BioTools Inc. $LAB	7/12/2023	$4.00	Overweight	KeyBanc Capital Markets
SomaLogic Inc. $SLGC	2/1/2022	$12.00	Buy	Stifel

More analyst ratings

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$LAB
$SLGC

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$LAB
$SLGC

$LAB
$SLGC
SEC Filings

SEC Form 425 filed by Standard BioTools Inc.

Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 8-K filed by Standard BioTools Inc.

$LAB
$SLGC
Insider Purchases

Director Casdin Partners Master Fund, L.P. bought $502,570 worth of shares (350,000 units at $1.44) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $10,053,280 worth of shares (7,700,000 units at $1.31) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $1,374,575 worth of shares (1,075,000 units at $1.28) (SEC Form 4)

$LAB
$SLGC
Analyst Ratings

Standard BioTools downgraded by TD Cowen with a new price target

Standard BioTools downgraded by KeyBanc Capital Markets

TD Cowen initiated coverage on Standard BioTools with a new price target

$LAB
$SLGC
Press Releases

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Standard BioTools Reports First Quarter 2026 Financial Results

Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026

$LAB
$SLGC
Insider Trading

Chief Financial Officer Kim Hanjoon Alex covered exercise/tax liability with 18,871 shares, decreasing direct ownership by 0.68% to 2,760,530 units (SEC Form 4) (tax liability)

SVP & Chief Business Officer Mackay Sean covered exercise/tax liability with 25,729 shares, decreasing direct ownership by 2% to 1,006,552 units (SEC Form 4) to satisfy tax liability

President & CEO Egholm Michael covered exercise/tax liability with 97,626 shares, decreasing direct ownership by 1% to 6,597,956 units (SEC Form 4) (for withholding tax)

$LAB
$SLGC
Financials

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Standard BioTools Reports Second Quarter 2025 Financial Results

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

$LAB
$SLGC
Leadership Updates

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

SomaLogic Announces Chief Financial Officer Transition

$LAB
$SLGC
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $LAB$SLGC

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $LAB$SLGC

$LAB$SLGC SEC Filings

SEC Form 425 filed by Standard BioTools Inc.

Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 8-K filed by Standard BioTools Inc.

$LAB$SLGC Insider Purchases

Director Casdin Partners Master Fund, L.P. bought $502,570 worth of shares (350,000 units at $1.44) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $10,053,280 worth of shares (7,700,000 units at $1.31) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $1,374,575 worth of shares (1,075,000 units at $1.28) (SEC Form 4)

$LAB$SLGC Analyst Ratings

Standard BioTools downgraded by TD Cowen with a new price target

Standard BioTools downgraded by KeyBanc Capital Markets

TD Cowen initiated coverage on Standard BioTools with a new price target

$LAB$SLGC Press Releases

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Standard BioTools Reports First Quarter 2026 Financial Results

Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026

$LAB$SLGC Insider Trading

Chief Financial Officer Kim Hanjoon Alex covered exercise/tax liability with 18,871 shares, decreasing direct ownership by 0.68% to 2,760,530 units (SEC Form 4) (tax liability)

SVP & Chief Business Officer Mackay Sean covered exercise/tax liability with 25,729 shares, decreasing direct ownership by 2% to 1,006,552 units (SEC Form 4) to satisfy tax liability

President & CEO Egholm Michael covered exercise/tax liability with 97,626 shares, decreasing direct ownership by 1% to 6,597,956 units (SEC Form 4) (for withholding tax)

$LAB$SLGC Financials

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Standard BioTools Reports Second Quarter 2025 Financial Results

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

$LAB$SLGC Leadership Updates

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

SomaLogic Announces Chief Financial Officer Transition

$LAB$SLGC Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Recent Analyst Ratings for
$LAB
$SLGC

Recent Analyst Ratings for
$LAB
$SLGC

$LAB
$SLGC
SEC Filings

$LAB
$SLGC
Insider Purchases

$LAB
$SLGC
Analyst Ratings

$LAB
$SLGC
Press Releases

$LAB
$SLGC
Insider Trading

$LAB
$SLGC
Financials

$LAB
$SLGC
Leadership Updates

$LAB
$SLGC
Large Ownership Changes